ArticleMedicine2026
A bibliometric and visual analysis of PRMTs research publications for cancer (2006-2024).
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundProtein arginine methyltransferases (PRMTs) have attracted considerable attention as potential targets for anticancer drug development. However, no bibliometric analysis of research articles on PRMTs in the field of oncology has been reported to date. To establish a knowledge map of PRMTs and cancer, summarize the current status and collaborative patterns of related publications, and explore research hotspots and future development prospects.
methodsUsing defined topic terms and their corresponding free-text terms, we searched the Web of Science Core Collection (WOSCC) database for relevant publications from January 1, 2006 to September 7, 2024. CiteSpace was used to perform bibliometric analyses of countries, institutions, authors, cited journals, keywords, and references. NoteExpress was used to import, manage, and add references.
resultsA total of 250 articles related to PRMTs and cancer were retrieved from WOSCC. Visual analysis showed a steady increase in the number of publications from 2006 to 2024. The United States had the highest centrality, whereas China had the highest publication count. The Chinese Academy of Sciences was the most productive institution. Mark T. Bedford was the most prominent and productive author. Cancer Cell had the highest centrality in this field. Based on keyword citation frequency, the leading research topics in current PRMTs and cancer studies were breast cancer, gene expression, coactivator-associated arginine methyltransferase 1 (CARM1), androgen receptor, and coactivator.
conclusionOverall, PRMTs and cancer research represents a promising research direction, and members of the PRMT family have potential utility as cancer biomarkers and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.